BCRX
BioCryst Pharmaceuticals, Inc.
14.18
-
0.07
0.49%
1 x 14.18
5 x 14.19
bid
ask
10:48 AM
timesize
Bearish
29
Bullish
78
sentiment
14.12
day range
14.37
7.61
52 week range
19.99
Prev Close14.25
Open14.34
Low14.12
High14.37
Volume324.56K
Avg. Volume3.10M
Market Cap2.64B
Inst. Own83.89%
Beta2.20
Short Ratio12.23
Div & Yield0.00 /
EPS-1.07
P/E
1yr Target18.60
50day MA11.44
200day MA12.90
^DJI
Dow Jones Industrial Average
33929.20
10:47 AM
-
51.10
0.15%
^IXIC
NASDAQ Composite
12943.80
10:47 AM
+
5.70
0.04%
^GSPC
S&P 500
4276.03
10:47 AM
+
1.99
0.05%
AAPL
Apple Inc.
174.14
10:48 AM
5 x 174.12
4 x 174.14
-
0.41
0.24%
GOOG
Alphabet Inc.
120.71
10:48 AM
9 x 120.22
40 x 120.21
+
0.39
0.32%
AMZN
Amazon.com, Inc.
141.79
10:48 AM
1 x 141.79
2 x 141.81
-
0.31
0.22%
MSFT
Microsoft Corporation
290.52
10:48 AM
13 x 289.72
8 x 289.75
-
0.80
0.27%
BABA
Alibaba Group Holding Limited
90.45
10:48 AM
1 x 90.42
1 x 90.45
+
0.68
0.76%
NFLX
Netflix, Inc.
242.53
10:48 AM
10 x 241.26
9 x 241.38
+
1.38
0.57%
TSLA
Tesla, Inc.
916.96
10:48 AM
10 x 909.74
14 x 910.16
+
4.97
0.54%
NVDA
NVIDIA Corporation
185.99
10:48 AM
11 x 184.10
8 x 184.09
+
2.64
1.44%
AMD
Advanced Micro Devices, Inc.
98.99
10:48 AM
1 x 98.98
1 x 98.99
+
0.72
0.73%
MU
Micron Technology, Inc.
62.65
10:48 AM
14 x 62.17
9 x 62.21
+
1.03
1.67%
SPY
SPDR S&P 500 ETF Trust
426.98
10:48 AM
9 x 425.88
8 x 426.04
+
0.33
0.08%
TQQQ
ProShares UltraPro QQQ
37.45
10:48 AM
11 x 36.99
8 x 37.00
+
0.15
0.40%
BRK-A
Berkshire Hathaway Inc.
454819.00
10:47 AM
10 x 454247.00
11 x 454615.00
-
2459.00
0.54%
| Day Gain | ||
| Gain | ||
| Market Val | ||
| Costs | ||
| Cash | ||
| Portfolio | ||
| Realized | ||
| Dividend |
News
...
| 2022-08-18 | NDAQ:BCRX | Press Release | BioCryst Pharmaceuticals Inc. | stockhouse.com • |
| Russell Investments Group Ltd. Has $1.31 Million Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) | defenseworld.net • |
| BioCryst Pharmaceuticals Inc (BCRX) Down 3.35% in Premarket Trading | investorsobserver.com • |
| Ginkgo Bioworks Holdings Inc (DNA) Down 3.48% in Premarket Trading | investorsobserver.com • |
| BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia | marketscreener.com • |
| State Board of Administration of Florida Retirement System Sells 13040 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) | defenseworld.net • |
Profile
...
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Earning
...
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2022-08-04 | 2022-06 | -0.36 | -0.32 | 0.04 | 11.11% |
| 2022-05-05 | 2022-03 | -0.39 | -0.4 | -0.01 | -2.56% |
| 2022-02-23 | 2021-12 | -0.31 | -0.4 | -0.09 | -29.03% |
| 2021-11-03 | 2021-09 | -0.3 | -0.33 | -0.03 | -10.00% |
| 2021-08-05 | 2021-06 | -0.22 | -0.24 | -0.02 | -9.09% |
| 2021-05-06 | 2021-03 | -0.26 | -0.36 | -0.1 | -38.46% |
Upgrade / Downgrade
...
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2022-08-08 | Oppenheimer | Downgrade | Outperform | Perform |
| 2022-08-05 | Barclays | Upgrade | Equal-Weight | |
| 2022-08-05 | Oppenheimer | Downgrade | Outperform | Perform |
| 2022-08-05 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| 2022-04-18 | Barclays | Downgrade | Overweight | Equal-Weight |
| 2022-04-12 | RBC Capital | Upgrade | Sector Perform |
Insider Holder
...
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2022-06-06 | ABERCROMBIE GEORGE B | Director | 12.87K | Stock Award(Grant) |
| 2022-06-06 | ASELAGE STEPHEN J | Director | 46.59K | Stock Award(Grant) |
| 2022-06-06 | GALSON STEVEN K | Director | 12.87K | Stock Award(Grant) |
| 2022-06-06 | HEGGIE THERESA | Director | 30.23K | Stock Award(Grant) |
| 2022-06-06 | HUTSON NANCY J | Director | 77.94K | Stock Award(Grant) |
| 2022-06-06 | INGRAM ROBERT ALEXANDER | Director | 95.00K | Stock Award(Grant) |
Institution Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-06-29 | Blackrock Inc. | 13.99M | 199.32M | 7.52% |
| 2022-06-29 | Vanguard Group, Inc. (The) | 13.81M | 196.79M | 7.43% |
| 2022-03-30 | Baker Brothers Advisors, LLC | 12.71M | 181.13M | 6.84% |
| 2022-03-30 | State Street Corporation | 7.46M | 106.34M | 4.01% |
| 2022-06-29 | Pictet Asset Management SA | 6.05M | 86.17M | 3.25% |
| 2022-06-29 | Fisher Asset Management, LLC | 5.22M | 74.34M | 2.81% |
Fund Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-06-29 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 7.26M | 103.50M | 3.91% |
| 2022-03-30 | Vanguard Total Stock Market Index Fund | 5.26M | 74.97M | 2.83% |
| 2022-06-29 | iShares Russell 2000 ETF | 4.17M | 59.43M | 2.25% |
| 2022-05-30 | Fidelity Select Portfolios - Biotechnology | 4.19M | 59.74M | 2.25% |
| 2022-04-29 | Lord Abbett Developing Growth Fund | 2.45M | 34.94M | 1.32% |
| 2022-03-30 | Vanguard Extended Market Index Fund | 2.39M | 34.03M | 1.29% |
Dividend
...
| Dividend | Date |
|---|---|
| 0 | 2014-06-11 |
| 0 | 2014-06-05 |
| 0 | 2014-05-20 |
| 0 | 2014-05-16 |
| 0 | 2014-04-02 |
This topic has been deleted. Only users with topic management privileges can see it.
-
@Biotech is Boomin, can you dumb it down for me , what you just posted, is it bad news, as in holding might not be a good idea? Yes, I am admitting I do not understand the terms you use. Ty for any anticipated reply.
-
8 monthes? Is that the time frame? Please tell me it will be sooner?
-
Thank you Ken for your kindness. Have a great night
-
Could kick myself for getting back in this, nothing will change. False hope is all this is.
-
5.05 seems to be its favorite number today.
-
Please let there be a possible buyout. Why won’t this thing blank or get off the pot already?
-
And here it comes, fishing time, so predictable
-
All biotech stocks are going up but here we are with this one. I wish I had something positive to say.
-
No news on BCRX , I will not add but will play ones with news today.
-
Grasping at straws
-
This has risen before and then it goes back down. Nothing new to see here. Same action different day. Fishes in the low end, then fishes some in the bit of a rise end, what is new here?
-
How low will she go? Order in for 4.50 ,average down and jump out of this Titanic if I can.
-
What I would like to know is how are they able to get away with Insider trading.
-
Nothing sinister going on with bcrx nothing to see here.
-
Needed the laugh. Ty. Lmao.
-
What a Sham
-
I see news on Bio Stocks, but Not on BCRX.
-
The post here showing the study won’t be done until May 2021 is helpful , that’s too long a wait for myself, in the meantime the stock gets manipulated enough to suck you in, then the price is dropped. Been following it for monthes. Sold, saw the brief tease of it going up bought back in too high, got burned again. All the notes of its potential does no good unless real news comes out by the Company. I’ll wait for the next fishing tease and get out once again, not willing to tie up my money for another 10 monthes.
-
Got sucked back in other day before it dropped. They win again. My own fault. Crazy stock. At loss now in a weak moment thinking it was going to keep rising.
-
GL all. I sold, based on my Luck that will probably make it skyrocket. Too weary to keep watching and hoping.
-
BioCryst Pharmaceuticals Inc (BCRX) Down 3.35% in Premarket Trading
investorsobserver.com • -
Ginkgo Bioworks Holdings Inc (DNA) Down 3.48% in Premarket Trading
investorsobserver.com • -
BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia
marketscreener.com • -
Top 5 2nd Quarter Trades of Biondo Investment Advisors, LLC
gurufocus.com • -
Options Bulls Blast Phama Stock on Lifted Clinical Hold
schaeffersresearch.com • -
3 Fast-Growing Stocks to Buy Now
fool.com • -
BioCryst to Report Second Quarter 2022 Financial Results on August 4
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
BioCryst: A Prudent Diversification
seekingalpha.com • -
7 Cheap Biotech Stocks to Buy Now
investorplace.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst to Report First Quarter 2022 Financial Results on May 5
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Falling
benzinga.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Plunging Today
benzinga.com • -
BioCryst Provides Tremendous Option Value
seekingalpha.com • -
BioCryst: Great Execution, Impressive Pipeline, Long Cash Runway
seekingalpha.com • -
7 Top Growth Stocks to Buy as We Step Into November
investorplace.com • -
BioCryst to Report Third Quarter 2021 Financial Results on November 3
globenewswire.com • -
7 Best Growth Stocks to Buy and Hold for the Next 10 Years
investorplace.com • -
2 Super-Charged Growth Stocks to Buy Now
fool.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
NICE Recommends BioCryst's Hereditary Angioedema Med
benzinga.com • -
What Wall Street Still Has Wrong. BioCryst To Become Next Rare Disease Giant
seekingalpha.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
BioCryst Appoints Dr. Steven Galson to Board of Directors
globenewswire.com • -
BioCryst Stock Jumps After Pulling Out $200M Equity Raise
benzinga.com • -
BioCryst Withdraws Public Offering
globenewswire.com • -
BioCryst Pharma Stock Heads Higher Thursday: Here's Why
benzinga.com • -
3 Biotech Stocks That Could Rocket Higher
fool.com • -
BioCryst to Report Second Quarter 2021 Financial Results on August 5
globenewswire.com • -
BioCryst Pharmaceuticals - Orladeyo Revenue Will Drive Share Price
seekingalpha.com • -
7 A-Rated Biotech Stocks to Buy Now
investorplace.com • -
BioCryst Pharmaceuticals: An Orphan Disease Innovator With More Upside
seekingalpha.com • -
Is BioCryst a Good Stock to Buy Now?
fool.com • -
BioCryst: Solid Delivery And Follow Through
seekingalpha.com • -
BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference
globenewswire.com • -
BCRX Stock Price: $15 Target By Piper Sandler
pulse2.com • -
BioCryst Technical Levels To Watch
benzinga.com •
